Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Canadian Cancer Trials Group
Age
65–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient must be eligible for the core CLC.2/A041202 protocol.
Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
Patient must be able (i.e. sufficiently fluent), and willing to complete the health utilities questionnaire in English or French. The baseline assessment must be completed within required timelines, prior to registration/randomization Inability (illiteracy in English or French, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the core protocol. However, ability but unwillingness to complete the questionnaires will make the patient ineligible for the core protocol.
Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
You may not be if
None
Clareo Health | Economic Analysis of Alliance A041202 CLL Study
